IGF-I CA19 repeat polymorphisms and cancer risk: a meta-analysis

Area of Science:

• Genetics
• Cancer Epidemiology
• Molecular Biology

Background:

• Insulin-like Growth Factor 1 (IGF-I) CA repeat polymorphisms, particularly the CA19 allele, have been linked to cancer risk.
• Previous studies on this association are conflicting and inconclusive.

Purpose of the Study:

• To conduct a meta-analysis evaluating the relationship between IGF-I CA19 repeat polymorphisms and cancer risk.
• To clarify the controversial findings regarding IGF-I CA19 repeat polymorphisms and cancer susceptibility.

Main Methods:

• Meta-analysis of 18 studies including 9,873 cancer patients and 15,607 controls.
• Utilized random-effects models to pool odds ratios (OR) for various genetic models (recessive, dominant, homozygote, heterozygote).
• Performed subgroup analyses, focusing on the recessive model, for specific cancers and populations.

Main Results:

• Overall meta-analysis did not show a significant association between IGF-I CA19 repeat polymorphisms and cancer risk across all models.
• Recessive genetic model: pooled OR = 0.69 (95% CI = 0.60-0.79).
• Subgroup analysis (recessive model) indicated a reduced risk in breast cancer (OR = 0.65), prostate cancer (OR = 0.68), and Caucasian populations (OR = 0.71).

Conclusions:

• IGF-I CA19 repeat polymorphisms are generally not a significant determinant of overall cancer susceptibility.
• Evidence suggests a potential protective effect of IGF-I CA19 repeat polymorphisms against specific cancers (e.g., breast, prostate) and in Caucasian populations under a recessive genetic model.